Sign in
CompletedPhase 3

Evaluating the Efficacy and Safety of Intra-articular Injection of HS-20116 in Patients With Knee Osteoarthritis

Key facts

Who runs it
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
192 people enrolled
Started
13 Aug 2024
Ended
27 Apr 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • HS-20116
  • Medical Chitosan (for intra-articular injection)
Record updated
9 July 2025

Who can take part

Age
40 years to 85 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Males or females aged 40-85 years (inclusive)
  • Body mass index (BMI) ≤ 35 kg/m2
  • Primary knee osteoarthritis in accordance with the clinical and radiological diagnostic criteria of the American College of Rheumatology (ACR), unilateral or bilateral femorotibial arthritis, with or without patellofemoral arthritis
  • A radiographic Kellgren and Lawrence (K\&L) grade of II to III in the treated knee within 6 months prior to randomization
  • Recurrent knee pain for at least 6 months at screening, with no or poor response to the first-line oral non-opioid analgesics and non-steroidal anti-inflammatory drugs (NSAIDS)
  • After a washout period of 48 h for analgesics, the degree of pain before bilateral knee injection was assessed using the WOMAC pain score (5-grade Likert method) prior to randomization, which should meet the following criteria:; Treated knee: WOMAC pain score of 7-17, of which item A1 was at least 2; Non-treated knee: WOMAC pain score of no more than 6
  • Completely free to move
  • Willing to undergo a 48-h analgesic washout period prior to visit

Who cannot take part

  • Concomitant synovial chondromatosis and villonodular synovitis of the knee
  • Concomitant autoimmune diseases, autoinflammatory diseases, or infectious arthritis, such as rheumatoid arthritis, psoriatic arthritis, articular chondrocalcinosis, gout, ankylosing spondylitis, and lupus erythematosus
  • Other concomitant pathological changes affecting joint treatment/evaluation, such as arthrodysplasia, ipsilateral hip osteoarthritis, aseptic bone necrosis, acromegaly, Paget's disease, hemophilia, hemochromatosis, lumbosacral radicular pain, femoral nerve or sciatic nerve radicular pain, venous or lymphatic obstruction, arteritis, tendon disorder, etc
  • Any knee injury, surgical history, or arthroscopy and treatment within 6 months prior to screening; or any surgery or other invasive operation expected to be performed during the trial
  • Prior injection with hyaluronic acid into the treated knee within 6 months prior to randomization
  • Patellofemoral osteoarthritis only, where symptoms including pain mostly originated from the patellofemoral joint (patellofemoral pain syndrome)
  • Skin infection, skin lesions, or chronic dermatosis at the puncture site
  • Onset of clinically significant knee effusion, knee inflammation or associated symptoms, or abnormal gross examination or volume of synovial fluid at the time of joint aspiration on the day of injection
  • Obvious varus or valgus deformity of the treated knee after clinical evaluation or imaging evaluation as judged by the investigator

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this trial is to evaluate the efficacy and safety of HS-20116 for intra-articular use in patients with symptomatic knee osteoarthritis.

The 2 groups in the trial

  • HS-20116Treatment being tested

    HS-20116 administered as a single intra-articular injection (3 mL per dose)

  • Medical Chitosan (for intra-articular injection)Existing treatment, for comparison

    Medical Chitosan administered as 2-3 intra-articular injections (2-3 mL per dose) in total.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Single-Blind, Active-controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Intra-articular Injection of HS-20116 in Patients With Knee Osteoarthritis
Record updated
9 July 2025